Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The threshold-suspend feature of sensor-augmented insulin pumps is designed to minimize the risk of hypoglycemia by interrupting insulin delivery at a preset sensor glucose value. We evaluated sensor-augmented insulin-pump therapy with and without the threshold-suspend feature in patients with nocturnal hypoglycemia. METHODS: We randomly assigned patients with type 1 diabetes and documented nocturnal hypoglycemia to receive sensor-augmented insulin-pump therapy with or without the threshold-suspend feature for 3 months. The primary safety outcome was the change in the glycated hemoglobin level. The primary efficacy outcome was the area under the curve (AUC) for nocturnal hypoglycemic events. Two-hour threshold-suspend events were analyzed with respect to subsequent sensor glucose values. RESULTS: A total of 247 patients were randomly assigned to receive sensor-augmented insulin-pump therapy with the threshold-suspend feature (threshold-suspend group, 121 patients) or standard sensor-augmented insulin-pump therapy (control group, 126 patients). The changes in glycated hemoglobin values were similar in the two groups. The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-suspend group than in the control group (980 ± 1200 mg per deciliter [54.4 ± 66.6 mmol per liter] × minutes vs. 1568 ± 1995 mg per deciliter [87.0 ± 110.7 mmol per liter] × minutes, P<0.001). Nocturnal hypoglycemic events occurred 31.8% less frequently in the threshold-suspend group than in the control group (1.5 ± 1.0 vs. 2.2 ± 1.3 per patient-week, P<0.001). The percentages of nocturnal sensor glucose values of less than 50 mg per deciliter (2.8 mmol per liter), 50 to less than 60 mg per deciliter (3.3 mmol per liter), and 60 to less than 70 mg per deciliter (3.9 mmol per liter) were significantly reduced in the threshold-suspend group (P<0.001 for each range). After 1438 instances at night in which the pump was stopped for 2 hours, the mean sensor glucose value was 92.6 ± 40.7 mg per deciliter (5.1 ± 2.3 mmol per liter). Four patients (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosis. CONCLUSIONS: This study showed that over a 3-month period the use of sensor-augmented insulin-pump therapy with the threshold-suspend feature reduced nocturnal hypoglycemia, without increasing glycated hemoglobin values. (Funded by Medtronic MiniMed; ASPIRE ClinicalTrials.gov number, NCT01497938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“People with diabetes who continue to have frequent and severe hypoglycemia and/or impaired awareness of hypoglycemia, despite educational interventions, may benefit from continuous subcutaneous insulin infusion (CSII) therapy or continuous glucose monitoring (CGM) or both (i.e. a sensor augmented pump), to reduce the risk of severe hypoglycemia (44)(45)(46)(47).”
From Hypoglycemia (2018) · cites this paper as [46]
In the citing paper
“Insulin pumps with automated low-glucose suspend and automated insulin delivery systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (126).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [126]
In the citing paper
“Reduction of nocturnal hypoglycemia in individuals with type 1 diabetes using insulin pumps with CGM is improved by automatic suspension of insulin delivery at a preset glucose level, with further improvements when using devices with predictive low-glucose insulin delivery suspension (24,25).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [24]
In the citing paper
“CGM with automated low glucose suspend and hybrid closed-loop systems have been shown to be effective in reducing hypoglycemia in type 1 diabetes (95).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [95]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794
Fear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579
Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes
Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3592 · Cited by 401
Adaptive increase in sample size when interim results are promising: a practical guide with examples
Mehta, C. R., & Pocock, S. J. (2011) · Statistics in Medicine · doi:10.1002/sim.4102 · Cited by 367
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Tanenberg, R. J., Newton, C. A., & Drake, A. J. (2010) · Endocrine Practice · doi:10.4158/ep09260.cr · Cited by 225
Increasing the sample size when the unblinded interim result is promising
Chen, Y. H. J., DeMets, D. L., & Gordon Lan, K. K. (2004) · Statistics in Medicine · doi:10.1002/sim.1688 · Cited by 207
Hypoglycemia in Type 1 Diabetes Mellitus
Cryer, P. E. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.003 · Cited by 205
Cited by
Items 401–500 of 662
De la bomba de insulina y el monitoreo continuo de glucosa al páncreas artificial
Apablaza, P., Néstor Soto, I., & Ethel Codner, D. (2017) · Revista médica de Chile · doi:10.4067/s0034-98872017000500011 · Cited by 18
Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?
Biester, T., Kordonouri, O., & Danne, T. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818763247 · Cited by 10
Petrovski, G., Khalaf, F. A., Hussain, K., Campbell, J., & Awwa, A. E. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0510-5 · Cited by 9
Gómez, A. M., Henao, D. C., Taboada, L. B., Leguizamón, G., Rondón, M., Múñoz, Ó., Maira, G., & Vargas, F. M. L. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.024 · Cited by 10
Automated Insulin Delivery in Children with Type 1 Diabetes.
Cengiz, E. (2020) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2019.10.012 · Cited by 7
Continuous Glucose Monitoring Adoption in the United Kingdom – An Economic and Policy Perspective
Oliver, N. S. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.73 · Cited by 9
“74 EUROPEAN ENDOCRINOLOGY For both adults and children, the use of CGM is an adjunct to education and support, and randomised clinical trials support CGM use independent of the insulin delivery modality (pump or multiple dose injection).(7,9,13) Importantly, NICE guidelines advocate an overall HbA1c target of 48 mmol/…”
MethodLei, M., Chen, D., Ling, P., Wang, C., Yang, D., Deng, H., Yang, X., Xu, W., & Yan, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15357 · Cited by 8
“32,33 Our study demonstrated that APS use could reduce nocturnal hypoglycaemia in pregnant women with T1DM, and 24-hour APS use also reduced the 24-hour TBR ( 2.8 mmol/L).”
BackgroundInfluentialXu, T., Jost, E., Messer, L. H., Cook, P. F., Forlenza, G. P., Sankaranarayanan, S., Fiesler, C. L., & Voida, S. (2024) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3613904.3642612 · Cited by 10
“Hybrid closed-loop systems and CGMs can lead to promising glycemic control outcomes (e.g., [4, 29]), notably addressing hypoglycemia, a pivotal facet of diabetes management [25], in vulnerable populations like young people.”
BackgroundOverview of novel routes of insulin: current status
ROY, L., & Bhattacharjee, M. (2020) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20204082 · Cited by 8
“Threshold suspend (TS) system can reduce severity of nocturnal hypoglycaemia by 30-40% and it has the ability to reduce hypoglycaemia duration; the system suspends the delivery of insulin for up to 2hours, if patient does not take action with a low glucose alarm.(39,40)”
BackgroundContinuous Glucose Monitoring in 2014
Bode, B. W., & Battelino, T. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1502 · Cited by 10
“However, the strength and importance of this study remains in the outcome of severe hypoglycemia, which was abolished with the use of low-glucose insulin suspension, similarly to the larger randomized controlled trial investigating the same technology (13), indicating that this technology can help those with impaired…”
Self-citationGarcía, L. P., Iriarte, M. J. G., & Mouriz, M. G. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.06.003 · Cited by 8
Anfinogenova, Y., Grakova, E. V., Shvedova, M., Kopeva, K. V., Teplyakov, A. T., & Popov, S. V. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9647-y · Cited by 8
Lepore, G., Bonfanti, R., Bozzetto, L., Blasi, V. D., Girelli, A., Grassi, G., Iafusco, D., Laviola, L., Rabbone, I., Schiaffini, R., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.12.001 · Cited by 12
A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes
Galderisi, A., & Sherr, J. L. (2019) · Pediatric Annals · doi:10.3928/19382359-20190725-03 · Cited by 8
Úbl, M., Koutný, T., Cioppa, A. D., Falco, I. D., Tarantino, E., & Scafuri, U. (2022) · Sensors · doi:10.3390/s22239445 · Cited by 9
“The simplest example of SAP therapy is the low-glucose suspend (LGS) controller [9].”
BackgroundDiabetes mellitus bei Kindern und Jugendlichen: Neue Herausforderungen der Telemedizin
Mirza, J., Mönkemöller, K., & Weiß, M. (2017) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-017-0334-9 · Cited by 8
“Dabei werden zu niedrige Glucosewerte vorausgesagt, die Insulinzufuhr schaltet sich automatisch ab und im Verlauf bei steigenden Glucosewerten wieder zu [1, 4, 14].”
BackgroundTiming of CGM initiation in pediatric diabetes: The CGM TIME Trial
Lawson, M. L., Verbeeten, K. C., Courtney, J. M., Bradley, B., McAssey, K., Clarson, C. L., Kirsch, S. E., Curtis, J. R., Mahmud, F. H., Richardson, C., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13144 · Cited by 8
Villafuerte, B., Frías, M. M., Martín, M. B. R., Valverde, R. Y., Gómez, M. Á. Á., & Castellanos, R. B. (2017) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.02.009 · Cited by 10
Available at a flash: a new way to check glucose
Thabit, H., Bally, L., & Hovorka, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31582-3 · Cited by 7
Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes
Tauschmann, M., & Hovorka, R. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360866 · Cited by 6
“Periodic insulin suspension over up to 2 h did not result in elevated glucose concentration as indicated by similar average glucose levels and HbA1c levels over a period of 3-6 months compared to insulin pump therapy and sensor augmented pump therapy [20,23].”
BackgroundInfluentialBaines, C. R., Vicendese, D., Cooper, D. M. L., McGuiness, W., & Miller, C. (2021) · Diving and Hyperbaric Medicine Journal · doi:10.28920/dhm51.3.240-247 · Cited by 7
Hypoglycemia in Type 1 Diabetes Mellitus
Şakar, K., & Çınar, N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004108 · Cited by 9
Registration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334993 · Cited by 7
Self-citationRegistration and Real-Life Studies on Automated Insulin Delivery Systems
Aktürk, H. K., Brown, S. A., Beck, R. W., Sherr, J. L., Bergenstal, R. M., Kovatchev, B. P., Vigersky, R. A., Breton, M. D., Hovorka, R., Klonoff, D. C., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0130 · Cited by 6
Self-citationThe connected health of cardiovascular medicine: current status and future directions
Ansary, A., Azuma, A., Komatireddy, R., & Barrett, P. M. (2013) · QJM · doi:10.1093/qjmed/hct159 · Cited by 6
“This is evidenced by capabilities such as sensor-augmented insulinpump therapy, which have already demonstrated effective reductions in hypoglycaemic events without increasing glycated haemoglobin values.(16) As an important risk factor for diabetes complications, adequately monitoring and managing blood pressure is o…”
Glycaemic control and novel technology management strategies in pregestational diabetes mellitus
Newman, C., Ero, A., & Dunne, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1109825 · Cited by 6
“2009 (36) Insulin pumps with threshold suspend features were introduced Safety net for people with hypoglycaemia which is superior to sensor augmented pump alone (2013)”
BackgroundContinuous Glucose Monitoring in 2013
Battelino, T., & Bode, B. W. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.1502 · Cited by 7
Self-citationCystic Fibrosis Related Diabetes: Potential pitfalls in the transition from paediatric to adult care
Middleton, P. G., Matson, A. G., Robinson, P. D., Holmes-Walker, D. J., Katz, T., & Hameed, S. (2014) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2014.05.003 · Cited by 6
“This has been shown to significantly reduce the frequency and duration of hypoglycaemia [18].”
BackgroundGarcía, L. P., Iriarte, M. J. G., & Mouriz, M. G. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2015.09.001 · Cited by 5
Real-World Glycemic Improvements with Hybrid Closed Loop Pumps in Youth with Type 1 Diabetes
Rolón, M. E. D. V., Brown, E. A., & Wolf, R. M. (2023) · Pediatric Diabetes · doi:10.1155/2023/6621706 · Cited by 5
“led to higher glucose monitoring satisfaction [8, 10].”
Hanaire, H. P., Atlan, C., Benhamou, P., Bismuth, É., Bonnemaison, É., Borot, S., Catargi, B., Charpentier, G., Farret, A., Filhol, N., et al. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30030-0 · Cited by 10
Orszag, A., Falappa, C. M., Lovblom, L. E., Partridge, H., Menezes, H. T., Boulet, G., Picton, P. E., Cafazzo, J. A., & Perkins, B. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.01.005 · Cited by 5
Recurrent severe hypoglycemia in Type 1 diabetes: potential for prevention?
Henriksen, M. M., Due-Andersen, R., Thorsteinsson, B., & Pedersen‐Bjergaard, U. (2014) · Diabetes Management · doi:10.2217/dmt.14.41 · Cited by 5
Martín, A. A., Pascual, A. C., Gómez, F. J., Albarrán, O. G., Gil, A. L., Botella-Serrano, M., & Sánchez, L. F. P. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.01.003 · Cited by 5
Aristizábal, N., Ramírez, Á., Hincapié-García, J. A., Laiton, E., Aristizábal, C., Cuesta, D., Monsalve, C., Hincapié, G. M. S., Zapata, E., Abad, V., et al. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.05.014 · Cited by 5
The Transformation of Diabetes Care Through the Use of Person-Centered Data
Mastrototaro, J. J. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815612093 · Cited by 5
“With sensor augmented pump platforms, the rate was reduced to 13 events per 100 patient years,(14) and with the MiniMed 530G system, the rate is further reduced to the point where users of the system’s Threshold Suspend feature experienced no severe hypoglycemic events in the 3-month ASPIRE In-Home study.(15) However,…”
MethodIs Continuous Glucose Monitoring Underappreciated in the UK?
Parkin, C. G., Holloway, M., Truesdell, J., & Walker, T. C. (2017) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2017.13.02.76 · Cited by 5
Thomakos, P., Mitrakou, A., Kepaptsoglou, O., Taraoune, I., Barreto, C., & Zoupas, C. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0889-7598 · Cited by 5
Abraham, M. B., Smith, G. J., Nicholas, J. A., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., Davis, E. A., Jones, T. W., on Behalf of the PLGM Study Group, et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0205 · Cited by 5
Hohendorff, J., Czupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Klupa, T., Myśliwiec, M., Szadkowska, A., Zozulińska‐Ziółkiewicz, D., & Malecki, M. T. (2021) · Archives of Medical Science · doi:10.5114/aoms/139025 · Cited by 10
Diabetestechnologie (Update 2023)
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Laimer, M., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02165-9 · Cited by 5
“Die Zeit im Zielbereich korreliert mit dem HbA1c-Wert hinsichtlich des Folgeerkrankungsrisiko ([10]; Abb.”
BackgroundMoreno-Fernández, J., Gómez, F. J., Moreno, M. Á. G., & Castano, J. P. (2016) · Journal of Diabetes Research · doi:10.1155/2016/4171789 · Cited by 5
“Main inclusion criteria included wearing RT-CGM >80% of time during the run-in phase [25].”
Refining the Closed Loop in the Data Age: Research-to-Practice Transitions in Diabetes Technology
Forlenza, G. P., Sankaranarayanan, S., & Maahs, D. M. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0055 · Cited by 5
“The In-Home ASPIRE study, a Phase 3 randomized controlled trial, found that TS use was associated with decreased frequence of nocturnal hypoglycemia and decreased area under the curve below 50 mg/dL in 247 patients with 1,438 instances of pump suspension.(4) In comparing the findings from the Phase 3 studies with the…”
BackgroundGargallo-Fernández, M., Martín, J. E. S., Peralta, F. G., Moreno, P. R., Martínez, A. M., Botella-Serrano, M., Pérez, C. T., & Fernández, J. L. (2016) · PubMed · doi:10.1016/j.endonu.2016.03.002 · Cited by 5
Jung, M., Lee, Y.-B., 진상만, & Park, S.-M. (2017) · arXiv (Cornell University) · doi:10.48550/arxiv.1704.08769 · Cited by 5
Heller, S. R., & Chow, E. (2014) · Medicine · doi:10.1016/j.mpmed.2014.09.008 · Cited by 4
van Laar, A., Gallardo‐Nuell, L., Pazmiño, S., Visser, M. M., Mertens, A. C., Vangoitsenhoven, R., Gillard, P., Al‐Ozairi, E., le Roux, C. W., Rosen, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103589 · Cited by 4
“15,21,22 Although there is evidence that specific technological innovations may improve glucose management in individuals living with type 1 diabetes, there is still a need to assess whether glucose management has also improved in the larger population of people with type 1 diabetes.”
Artificial intelligence-based decision support systems for diabetes
Contreras, I., Bertachi, A. H., Biagi, L., Oviedo, S., Ramkissoon, C. M., & Vehí, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817133-2.00014-8 · Cited by 4
Lee, Y. J., Lee, Y. A., Kim, J. H., Chung, H. R., Gu, M. J., Kim, J. Y., & Shin, C. H. (2020) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040048.024 · Cited by 4
Gjessing, H. J., Jørgensen, U. L., Møller, C. C., Pedersen, J., Grodum, E., & Schousboe, K. (2014) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2014.44042 · Cited by 4
“Use of insulin pumps with glucose sensor and low suspend function protects against development of severe hypoglycaemia [19] [20].”
BackgroundNew Technologies for Glucose Monitoring and Insulin Administration
Horwitz, D., & Klonoff, D. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch30 · Cited by 4
Self-citationGeorga, E. I., Fotiadis, D. I., & Tigas, S. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804831-3.00001-7 · Cited by 4
Perspectives on Continuous Glucose Monitoring Technology
Gao, F., & Jia, W. (2018) · Springer eBooks · doi:10.1007/978-981-10-7074-7_20 · Cited by 6
A general view of epidemiology of hypoglycemia in type 1 and type 2 diabetes mellitus
Brož, J., & Urbanová, J. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.050 · Cited by 5
“Systémy pumpa – senzor vybavené možností automa tického zastavení dodávky inzulinu prokázaly schopnost snížení nočních hypoglykemií o 38 % [25,26], ve studii s dětmi a adolescenty došlo i ke snížení těžkých hypo glykemií [27].”
Shah, V. N., Rewers, A. H., & Garg, S. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00013-2 · Cited by 4
Self-citationTechnologies in the management of type 1 diabetes
SNAITH, J. R., & Holmes-Walker, D. J. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.50946 · Cited by 4
Falla autonómica asociada a hipoglucemia
Houssay, S., Recalde, M., Rey, M. G., García, C., Urdaneta, R., Huber, F., Flores, C. L. U., Domínguez, C., & Nader, E. (2021) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v55i2.473 · Cited by 4
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00769-1 · Cited by 5
Courtney, A., Smith, D., & Forde, H. E. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03322-9 · Cited by 4
mHealth Technologies in Pre-Diabetes and Diabetes Care
Brooke, M. J., & Rege, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00016-8 · Cited by 4
Human fetal pancreatic islet-like structures as source material to treat type 1 diabetes
Ikeda, Y., & Kudva, Y. (2013) · Stem cell research & therapeutics · doi:10.1186/scrt389 · Cited by 4
“The recent approval of the first closed loop therapy for the disorder in the US by the Food and Drug Administration, following the publication of its efficacy, represents a major step forward in treatment of the disorder [3].”
BackgroundInfluentialUpcoming Devices for Diabetes Management: The Artificial Pancreas as the Hallmark Device
Lee, S. W., & Welsh, J. B. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0303 · Cited by 4
“22 Presently, the predictive low glucose suspend feature is being evaluated for safety and efficacy as well.”
Self-citationSuccesses and Disappointments with Clinical Islet Transplantation
Cravedi, P., Ruggenenti, P. L., & Remuzzi, G. (2013) · Springer eBooks · doi:10.1007/978-94-007-6884-0_23-1 · Cited by 3
Selim, K. K., Farag, A., & Abdellatif, S. O. (2026) · Microsystem Technologies · doi:10.1007/s00542-026-06022-3 · Cited by 3
“When glucose levels exceed a certain threshold, the sys - tem administers a predetermined amount of insulin to lower blood sugar levels (Bergenstal et al. 2013).”
Ampudia‐Blasco, F. J., Ugarte, E., Chico, A. I., García-Alemán, J., & Galan-Barroso, M. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221087270 · Cited by 3
Fezzi, C., Refahi, H., Albuisson, É., & Feigerlová, E. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101968 · Cited by 3
Early Stages of Automated Insulin Delivery
Zisser, H., Hovorka, R., Basu, A., Battelino, T., Boughton, C. K., Breton, M. D., Buckingham, B. A., Brown, S. A., Cherñavvsky, D. R., Dassau, E., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18802.hz · Cited by 3
“88 The Medtronic 670G was the fi rst commercial hybrid AID pump approved for people over 14 years old in 2016, for children seven to 13 in 2018, and two to six years old in 2020.”
Self-citationPredicting Nocturnal Hypoglycemia Using a Non-parametric Insulin Action Model
Ståhl, F. L., Johansson, R., & Olsson, M. L. (2015) · Conference proceedings/Conference proceedings - IEEE International Conference on Systems, Man, and Cybernetics · doi:10.1109/smc.2015.280 · Cited by 5
“Studies show that the system could further reduce the duration and frequency of nocturnal hypoglycemia [8].”
BackgroundAuf dem Weg zum Closed-Loop – Ziel und Realität
Biester, T., Danne, T., & Kordonouri, O. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-119492 · Cited by 3
Continuous Glucose Monitoring Efficacy in Routine Use
Battelino, T. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00275 · Cited by 3
Habteab, A., Castañeda, J., de Valk, H. W., Choudhary, P., Bosi, E., Lablanche, S., de Portu, S., Silva, J. D., Vorrink, L., Shin, J., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0495 · Cited by 3
“Joseph’s Health Care, London, Ontario, Canada (11): Irene Hramiak (I), Tamara Spaic (I), and Marsha Driscoll (C).”
BackgroundPredictive low-glucose suspend system and glycemic variability
Evin, F., Ata, A., Er, E., Demir, G., Çetin, H., Altınok, Y. A., Özen, S., Darcan, Ş., & Gökşen, D. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00957-1 · Cited by 3
Insulin pumps: are services and health equity undermining technological progression?
Curtis, L. R., Alington, K., & Partridge, H. L. (2021) · Practical Diabetes · doi:10.1002/pdi.2349 · Cited by 4
Kolassa, R. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1148-6 · Cited by 3
Moreno-Fernández, J., Beato-Víbora, P. I., Olvera, P., García-Seco, J. A., Gallego-Gamero, F., Herrera, M. T., & Muñoz‐Rodríguez, J. R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109093 · Cited by 3
Post-graduate medical education in the time of COVID-19: Not a remotely simple task
Romeo, G. R., Shaikh, Y. A., & Middelbeek, R. J. W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.980505 · Cited by 3
“We applaud new programs established within the American Rescue Plan Act (ARPA) (21) that fund broadband infrastructure projects andprovidefinancial assistance for Internet costs to eligible households; yet, in the short term inequalities in distribution of high-speed connectivity in rural areas and among minorities an…”
MethodUpdate information on type 1 diabetes in children/adolescents and adults
Miura, J., & Uchigata, Y. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13961 · Cited by 5
Approach to the Hypoglycemic Patient
Chang, M., & Willis, G. C. (2023) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2023.06.004 · Cited by 3
Modern strategies for management of glycaemia in type 1 diabetes
Neupane, S., & Evans, M. L. (2014) · Medicine · doi:10.1016/j.mpmed.2014.09.006 · Cited by 3
Patrascioiu, I., Quirós, C., Ríos, P., Ruíz, M., Mayordomo, R., Conget, I., & Giménez, M. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0266 · Cited by 5
“A recent prospective trial 4 revising the threshold-suspend feature for the sensor-augmented pump therapy demonstrated its utility in reducing nocturnal hypo-glycemia without increasing HbA 1c values.”
Toward Automation of Insulin Delivery - Management Solutions for Type 1 Diabetes
Nimri, R., & Phillip, M. (2015) · Endocrine development · doi:10.1159/000439321 · Cited by 3
Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial
Tauschmann, M., Allen, J. M., Wilinska, M. E., Ruan, Y., Thabit, H., Acerini, C. L., Dunger, D. B., & Hovorka, R. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816678631 · Cited by 3
“CGM-assisted therapeutic approaches beyond diabetes monitoring include threshold-suspend and predictive low glucose management insulin pump therapy, which temporarily interrupt insulin delivery at predefined low sensor glucose levels, and thus may alleviate the burden of hypoglycemia.(4,5) Closed-loop (CL) systems exp…”
BackgroundCastle, J. R. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0052 · Cited by 3
“In a study of 247 patients with documented nocturnal hypoglycemia, the threshold suspend feature significantly reduced hypoglycemia; the percent time of the sensor reading <50 mg/dL was decreased by 57%.(3) However, the Medtronic 530G system was not designed to prevent hypoglycemia, only to reduce the severity and dur…”
BackgroundBiester, T., Remus, K., Holder, M., Aschemeier, B., Kieninger‐Baum, D., Wadien, T., Kordonouri, O., Danne, T., & Thomas, A. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-114867 · Cited by 3
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3388 · Cited by 6
Reducing Hypoglycemia in Type 1 Diabetes: An Incremental Step Forward
Hirsch, I. B. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0174 · Cited by 3
Implications of Predictive Low-Glucose Management System in Hybrid of Full Closed Loop System
Choudhary, P. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0227 · Cited by 3
“4 However, threshold suspend systems can only mitigate the duration of hypoglycemia, not prevent hypoglycemia happening, and this is where the concept of suspending insulin delivery in advance of impending hypoglycemia using predictive algorithms is so exciting.”
Glucose sensing technology—current practice?
Forde, H. E., Browne, S., Smith, D., & Tormey, W. P. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1800-7 · Cited by 3
7 th Annual Symposium on Self-Monitoring of Blood Glucose (SMBG), May 8–10, 2014, Helsinki, Finland
Parkin, C. G., Mlinac, A., & Hinzmann, R. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0239 · Cited by 2
Khowaja, A. A., Adil, L., Dwyer, T., Barrett, T. S., & Alkhaddo, J. B. (2025) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2025.100274 · Cited by 2
Islet Cell or Pancreas Transplantation
Piemonti, L., Socci, C., Nano, R., Maffi, P., & Secchi, A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_23 · Cited by 2
Gargallo-Fernández, M., Martín, J. E. S., Peralta, F. G., Moreno, P. R., Martínez, A. M., Botella-Serrano, M., Pérez, C. T., & Fernández, J. L. (2015) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endien.2017.10.009 · Cited by 6
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01048-x · Cited by 2
Toffanin, C., & Magni, L. (2023) · Control Engineering Practice · doi:10.1016/j.conengprac.2023.105578 · Cited by 3
Clinical Practice Update: Inpatient Insulin Pump and Integrated Insulin Delivery Systems
Nguyen, S., Davis, G. M., & Vasudevan, M. M. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_7 · Cited by 2
Boughton, C. K., Allen, J. M., Ware, J., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/ktfr5698 · Cited by 2
Dispositivi indossabili per la gestione del diabete
Carlucci, F., Tabucchi, A., Fiorini, M., Galasso, L., & Terreni, A. (2025) · Biochimica Clinica · doi:10.23736/s0393-0564.25.00067-6 · Cited by 2
Dayal, D., Sharma, S., Sachdeva, N. K., Bhalla, A., & Attri, S. V. (2014) · Journal of Diabetology · doi:10.4103/2078-7685.198299 · Cited by 2
Jenkins, A. J., Kilov, G., SCOTT, E. S., Fulcher, G., O'Neal, D. N., & Januszewski, A. S. (2018) · Madridge Journal of Diabetes · doi:10.18689/mjd-1000111 · Cited by 2
“25%) for insulin pump users, and also increase time in target glucose ranges and reduce hypoglycaemia, in particular severe hypoglycaemia, and low glucose time [31-33].”
BackgroundMethodSensor‐augmented pump therapy: review of new NICE diagnostic guidance
Raj, S., & Chakera, A. J. (2016) · Practical Diabetes · doi:10.1002/pdi.1999 · Cited by 2
Metadata
- Authors
- Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R.
- Affiliations
- Park Nicollet Health Services (US)
- Mills Peninsula Health Services (US)
- University of Colorado Denver (US)
- Atlanta Diabetes Associates (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 224-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102877966
- Cited by
- 652
- References
- 21
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 18 · 2023: 36 · 2022: 30 · 2021: 41 · 2020: 39 · 2019: 62 · 2018: 75 · 2017: 80 · 2016: 82 · 2015: 74 · 2014: 73 · 2013: 17
- FWCI
- 64.50
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by-nc
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Repositorio Institucional (Pontificia Universidad Javeriana) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- sensor-augmented pump, insulin pump therapy, nocturnal hypoglycemia, type 1 diabetes, HbA1c, hypoglycemia prevention, continuous glucose monitoring, glycemic control, hypoglycemic events, hypoglycemia severity, hypoglycemia duration
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.